Publikationen der AG Behrens

Auswahl wissenschaftlicher Publikationen

Link zu Pubmed:

https://pubmed.ncbi.nlm.nih.gov/?term=behrens+g&sort=date

  1. Behrens GMN, Barros-Martins J, Cossmann A, Morillas Ramos G, Stankov MV, Odak I, Dopfer-Jablonka A, Hetzel L, Köhler M, Patzer G, Binz C, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Krähling V, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B*, Hammerschmidt SI, Förster R. BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nat Comm 2022 Aug 18;13(1):4872
  2. Arora P, Kempf A, Nehlmeier I, Graichen L, Schulz S, Cossmann A, Stankov MV, Jäck H-M, Behrens GMN, Pöhlmann S, Hoffmann M. Augmented neutralization resistance of emerging Omicron subvariants BA.2.12.1, BA.4 and BA.5. Lancet Infect Dis 2022 Jun 28:S1473-3099(22)00422-4.
  3. Arora P, Zhang L, Krüger N, Rocha C, Sidarovich A, Schulz S, Kempf A, Graichen L, Moldenhauer A-S, Cossmann A, Dopfer-Jablonka A, Behrens GMN, Jäck H-M, Winkler MS, Pöhlmann S, Hoffmann M. SARS-CoV-2 Omicron subvariants show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host Microbe 2022 May 6 doi: 10.1016/j.chom.2022.04.017
  4. Lemoine M, Assoumou L, Girard PM, Valantin MA, Katlama C, De Wit S, Campa P, Rougier H, Meynard J-L, Necsoi C,  Huefner AD, van Lunzen J, Schulze Zur Wiesch J, Bastard JP, Fellahi S, Mauss S, Stankov MV, Baumgarten A, Post G, Serfaty L, Ratziu V, Menu Y, Schlue J, Bedossa P, Capeau J, Costagliola D, Behrens GMN*, Ingiliz P*, on behalf of the ANRS-ECHAM group. Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study. Clin Gastroenterol Hepatol 2022 Apr 15:S1542-3565(22)00390-1 (*equal contribution)
  5. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, Cossmann A, Manger B, Baier E, Tampe B, Moerer O, Dickel S, Dopfer-Jablonka A, Jäck H-M, Behrens GMN, Winkler MS, Pöhlmann S, Hoffmann M. Comparable neutralization evasion by SARS-CoV-2 Omicron subvariants BA.1, BA.2 and BA.3. Lancet Infect Dis 2022 Jun;22(6):766-767.
  6. Arora P, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, Jäck H-M, Cossmann A, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M.  SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) efficiently evade from neutralization by antibodies elicited upon infection or vaccination. Cell Rep 2022 May 3;39(5):110754.
  7. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer A-L, Winkler MS, Lier M, Dopfer-Jablonka A,  Jäck H-M*, Behrens GMN*, Pöhlmann S*. The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic. Cell 2022, 184: 1-10. (*equal contribution)
  8. Arora P, Kempf A, Nehlmeier I, Sidarovich A, Krüger N, Graichen L, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination, Cell Rep 2021; 37: 109825.
  9. Behrens GMN, Cossmann A, Stankov MV, Nehlmeier I, Kempf A, Hoffmann M, Pöhlmann S. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet 2021; 398: 1041-1042.
  10. Lazarus J, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, Bekker LG, Bhagani S, Brown D, Brown G, Buchbinder S, Caceres C, Cahn P, Carrieri P, Caswell G, Cooke G, d'Arminio Monforte A, Dedes N, Del Amo J, Elliott R, El-Sadr W, Fuster-RuizdeApodaca MJ, Guaraldi G, Hallett T, Harding R, Hellard M, Jaffar S, Kall M, Klein M, Lewin S, Mayer K, Pérez-Molina JA, Moraa D, Naniche D, Nash D, Noori T, Pozniak A, Rajasuriar R, Reiss P, Rizk N, Rockstroh J, Romero D, Sabin C, Serwadda D, Waters L. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat Commun 2021 Jul 16;12(1):4450
  11. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B*, Förster R*, Behrens GMN*. Immune responses against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 Jul 14. doi: 10.1038/s41591-021-01449-9. (*equal contribution)
  12. Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, Arora P, Sidarovich A, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021 Jun 29:109415.
  13. Stankov MV, Cossmann A, Bonifacius A, Dopfer-Jablonka A, Morillas Ramos G, Gödecke N, Zychlinsky Scharff A, Happle C, Boeck A-L, Tran AT, Pink I, Hoeper MM, Blasczyk R, Winkler MS, Nehlmeier I, Kempf A, Hofmann-Winkler H, Hoffmann M, Eiz-Vesper B, Pöhlmann S,  Behrens GMN. Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination. Clin Infect Dis. 2021 Jun 16:ciab555.
  14. Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, Gödecke N, Yilmaz M, Kraft ARM, Hoeper MM, Pink I, Schmidt JJ, Li Y, Welte T, Maecker-Kolhoff B, Martens J, Berger MM, Lobenwein C, Stankov MV, Cornberg M, David S, Behrens GMN, Witzke O, Blasczyk R, Eiz-Vesper B. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021 Feb 9;54(2):340-354.e6.
  15. Gaborit BJ, Bergmann J-F, Mussini C, Arribas JR, Behrens G, Walmsley S, Pozniak A, Raffi F. Plea for multitargeted interventions for severe COVID-19. Lancet Infect Dis. 2020 Apr 21 doi: 10.1016/S1473-3099(20)30312-1
  16. Safreed-Harmon K, Anderson J, Azzopardi-Muscat N, Behrens GMN, d'Arminio Monforte A, Davidovich U, Del Amo J, Kall M, Noori T, Porter K, Lazarus JV. Reorienting health systems to care for people with HIV beyond viral suppression.  Lancet HIV 2019; 6(12):e869-e877.
  17. van den Berk GEL, Leoni MC, Behrens GMN, Taljaard J, Arends JE. Improving HIV-related care through eHealth. Lancet HIV 2020 Jan;7(1):e8-e10.
  18. Sogkas G, Ernst D, Atschekzei F, Jablonka A, Schmidt RE, Behrens GMN, Stoll M. Consider Syphilis in Case of Lymphopenia in HIV-Infected Men Who Have Sex with Men (MSM): A Single-center, Retrospective Study. Infect Dis Ther 2018; 7(4):485-494.
  19. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, ChomontN, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D,Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med 2016; 22(8):839-50.
  20. Stankov MV, El Khatib M, Kumar Thakur B, Heitmann K, Panayotova-Dimitrova D, Schoening J, Bourquin JP, Schweitzer N, Leverkus M, Welte K, Reinhardt D, Li Z, Orkin SH, Behrens GM, Klusmann JH. Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy. Leukemia 2014; 28(3):577-88.
  21. Kühl A, Münch J, Sauter D, Bertram S, Glowacka I, Steffen I, Specht A, Hofmann H, Schneider H, Behrens G, Pöhlmann S. Calcium-modulating cyclophilin ligand does not restrict retrovirus release. Nat Med 2010; 16(2):155-6; author reply 157.
  22. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D, Davey G, Kupresanin F, Li M, Maraskovsky E, Belz GT, Carbone FR, Shortman K, Heath WR, Villadangos JA. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A 2006; 103(28):10729-34.
  23. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF, Belz GT, Carbone FR, Crabb BS, Heath WR, Villadangos JA. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7(2):165-72.
  24. Behrens GM, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G, Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 2002; 110(9):1319-27.
  25. Belz GT, Behrens GM, Smith CM, Miller JF, Jones C, Lejon K, Fathman CG, Mueller SN, Shortman K, Carbone FR, Heath WR. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002; 196(8):1099-104.
  26. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet 1999; 354(9172):76.
  27. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351(9120):1958.
  28. Behrens G, Knuth C, Schedel I, Mendila M, Schmidt RE. Highly active antiretroviral therapy. Lancet 1998; 351(9108):1057-8; author reply 1058-9.
  29. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998; 91(1):181-6.